Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation

A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease

(2014) Marvin E. Reid et al.   AMERICAN JOURNAL OF HEMATOLOGY

Stroke With Transfusions Changing to Hydroxyurea (SWiTCH)

(2012) R. E. Ware et al.   BLOOD

HDAC inhibitor-based therapies: Can we interpret the code?

(2012) Maria New et al.   Molecular Oncology

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)

(2011) Winfred C Wang et al.   LANCET

Health-related quality of life in adults with sickle cell disease (SCD): A report from the comprehensive sickle cell centers clinical trial consortium

(2010) Carlton Dampier et al.   AMERICAN JOURNAL OF HEMATOLOGY

Hydroxyurea for Children with Sickle Cell Disease

(2010) Matthew M. Heeney et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Sickle-cell disease

(2010) David C Rees et al.   LANCET

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease

(2010) James E. Bradner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)

(2009) E. Voskaridou et al.   BLOOD